CoChat
Sign Up
Cited by 21MicroRNA in disease regulationLiver Disease Diagnosis and TreatmentLiver physiology and pathology

The miR-23–27–24 cluster: an emerging target in NAFLD pathogenesis

Open access
Ru, Lin, Wang, Xiao-mei, Niu, Jun-qi·2022·Acta Pharmacologica Sinica
DOI 10.1038/s41401-021-00819-wPMC PMC9061717
Open this paper in CoChat — free accountOpen PDF

Abstract

The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing globally, being the most widespread form of chronic liver disease in the west. NAFLD includes a variety of disease states, the mildest being non-alcoholic fatty liver that gradually progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and eventually hepatocellular carcinoma. Small non-coding single-stranded microRNAs (miRNAs) regulate gene expression at the miRNA or translational level. Numerous miRNAs have been shown to promote NAFLD pathogenesis and progression through increasing lipid accumulation, oxidative stress, mitochondrial damage, and inflammation. The miR-23-27-24 clusters, composed of miR-23a-27a-24-2 and miR-23b-27b-24-1, have been implicated in various biological processes as well as many diseases. Herein, we review the current knowledge on miR-27, miR-24, and miR-23 in NAFLD pathogenesis and discuss their potential significance in NAFLD diagnosis and therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41401-021-00819-w

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-23, miR-27, and miR-24 can sometimes share a common target site, but their biological functions are distinct due to variations in expression regulation.

    “Sometimes, miR-23, miR-27, and miR-24 can share a common target site [9], but their biological functions are distinct due to variations in expression regulation.”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [9]

    The citation is attached to the shared-target clause. The “Interactive Functions of miR-23, miR-27, and miR-24” section reports that all three target SMAD5, but it does not establish that they bind the same target site. The later clause about distinct functions due to expression regulation is not attached to this citation. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • In vivo and in vitro experiments indicated that miR-23a-3p can combine with PGC-1α to advance lipid metabolism and lessen alcoholic liver injury.

    “In vivo and in vitro experiments have indicated that it can combine with peroxisome proliferator activated receptor-gamma coactivator 1-alpha (PGC -1α) to advance lipid metabolism and lessen alcoholic liver injury [9,19].”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [9]

    The ‘MIR-24 AND MIR-23’ section links miR-23a to PGC-1α, but reports that downregulating miR-23a increased PGC-1α expression and reduced HepG2 cell apoptosis. It also reports that attenuating miR-23a alleviated hepatic steatosis. These passages do not establish that miR-23a-3p binds PGC-1α to improve lipid metabolism or lessen alcoholic liver injury, nor do they describe both in vivo and in vitro experiments for that claim. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • miR-23a-3p can be mediated by isoglycyrrhizinate, and its expression is heightened in alcoholic liver disease.

    “Among them, miR-23a-3p can be mediated by isoglycyrrhizinate, and its expression is heightened in alcoholic liver disease.”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [9]

    The “MIR-24 AND MIR-23” section discusses miR-23a in NAFLD, hepatic fibrosis and steatosis, but does not link miR-23a-3p to isoglycyrrhizinate or report heightened expression in alcoholic liver disease. Searches for “isoglycyrrhizinate” and “alcoholic liver disease” found no passage establishing either part of the claim; pages were not supplied in our copy. (LLM, conf=0.73)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 96

  1. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121-40.
  2. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastro- enterology. 2015;148:547-55.
  3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epi- demiology of nonalcoholic fatty liver disease-Meta-analytic assessment of pre- valence, incidence, and outcomes. Hepatology. 2016;64:73-84.
  4. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183-91.
  5. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38.
  6. Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastro- enterology. 2015;149:1784-93.
  7. Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol. 2020;55:142-58.
  8. Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology. 2016;63:2032-43.
  9. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-54.
  10. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175-205.
  11. Su Q, Kumar V, Sud N, Mahato RI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54-63.
  12. Zeng HC, Bae Y, Dawson BC, Chen Y, Bertin T, Munivez E, et al. MicroRNA miR- 23a cluster promotes osteocyte differentiation by regulating TGF-β signalling in osteoblasts. Nat Commun. 2017;8:15000.
  13. Kurkewich JL, Hansen J, Klopfenstein N, Zhang H, Wood C, Boucher A, et al. The miR-23a~27a~24-2 microRNA cluster buffers transcription and signaling path- ways during hematopoiesis. PLoS Genet. 2017;13:e1006887.
  14. Rice MA, Ishteiwy RA, Magani F, Udayakumar T, Reiner T, Yates TJ, et al. The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related. Oncogene. 2016;35:4752-61.
  15. Chen WJ, Yin K, Zhao GJ, Fu YC, Tang CK. The magic and mystery of microRNA- 27 in atherosclerosis. Atherosclerosis. 2012;222:314-23.
  16. Cai C, Min S, Yan B, Liu W, Yang X, Li L, et al. MiR-27a promotes the autophagy and apoptosis of IL-1β treated-articular chondrocytes in osteoarthritis through PI3K/AKT/mTOR signaling. Aging (Albany NY). 2019;11:6371-84.
  17. Yang Z, Xiao Z, Guo H, Fang X, Liang J, Zhu J, et al. Novel role of the clustered miR-23b-3p and miR-27b-3p in enhanced expression of fibrosis-associated genes by targeting TGFBR3 in atrial fibroblasts. J Cell Mol Med. 2019;23:3246-56.
  18. Tripathi A, Volsko C, Garcia JP, Agirre E, Allan KC, Tesar PJ, et al. Oligodendrocyte intrinsic miR-27a controls myelination and remyelination. Cell Rep. 2019;29:904-919.e909.
  19. Li X, Xu M, Ding L, Tang J. MiR-27a: a novel biomarker and potential therapeutic target in tumors. J Cancer. 2019;10:2836-48.
  20. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92:1023-33.
  21. Krssak M, Roden M. The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans. Rev Endocr Metab Disord. 2004;5:127-34.
  22. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J. 2009;276:2348-58.
  23. Kim SY, Kim AY, Lee HW, Son YH, Lee GY, Lee JW, et al. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun. 2010;392:323-8.
  24. Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, Ailhaud G, et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun. 2009;390:247-51.
  25. Siniakova NA, Kulikov AV. [Coexpression of genes located in the 111.35-116.16 Mb of chromosome 13 in mice with different predisposition to catalepsy]. Mol Biol (Mosk). 2014;48:733-41.
  26. Liu W, Ma C, Yang B, Yin C, Zhang B, Xiao Y. LncRNA Gm15290 sponges miR-27b to promote PPARγ-induced fat deposition and contribute to body weight gain in mice. Biochem Biophys Res Commun. 2017;493:1168-75.
  27. Kulyté A, Kwok KHM, de Hoon M, Carninci P, Hayashizaki Y, Arner P, et al. MicroRNA-27a/b-3p and PPARG regulate SCAMP3 through a feed-forward loop during adipogenesis. Sci Rep. 2019;9:13891.
  28. Deng K, Ren C, Fan Y, Liu Z, Zhang G, Zhang Y, et al. miR-27a is an important adipogenesis regulator associated with differential lipid accumulation between intramuscular and subcutaneous adipose tissues of sheep. Domest Anim Endocrinol. 2020;71:106393.
  29. Hsu CC, Lai CY, Lin CY, Yeh KY, Her GM. MicroRNA-27b depletion enhances endotrophic and intravascular lipid accumulation and induces adipocyte hyperplasia in zebrafish. Int J Mol Sci. 2017;19:93.
  30. Zhu Y, Zhang X, Ding X, Wang H, Chen X, Zhao H, et al. miR-27 inhibits adi- pocyte differentiation via suppressing CREB expression. Acta Biochim Biophys Sin (Shanghai). 2014;46:590-6.
  31. Butterwith SC, Wilkie RS, Clinton M. Treatment of pluripotential C3H 10T1/2 fibroblasts with bone morphogenetic protein-4 induces adipocyte commitment. Biochem Soc Trans. 1996;24:163s.
  32. Bowers RR, Kim JW, Otto TC, Lane MD. Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. Proc Natl Acad Sci USA. 2006;103:13022-7.
  33. Tang QQ, Otto TC, Lane MD. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA. 2004;101:9607-11.
  34. Chen SZ, Xu X, Ning LF, Jiang WY, Xing C, Tang QQ, et al. miR-27 impairs the adipogenic lineage commitment via targeting lysyl oxidase. Obesity (Silver Spring). 2015;23:2445-53.
  35. Kang T, Lu W, Xu W, Anderson L, Bacanamwo M, Thompson W, et al. MicroRNA- 27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mito- chondrial function in human adipose-derived stem cells. J Biol Chem. 2013;288:34394-402.
  36. Murata Y, Yamashiro T, Kessoku T, Jahan I, Usuda H, Tanaka T, et al. Up-regulated MicroRNA-27b promotes adipocyte differentiation via induction of Acyl-CoA thioesterase 2 expression. Biomed Res Int. 2019;2019:2916243.
  37. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313-27.
  38. Zhang M, Sun W, Zhou M, Tang Y. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. Sci Rep. 2017;7:14493.
  39. Teimouri M, Hosseini H, Shabani M, Koushki M, Noorbakhsh F, Meshkani R. Inhibiting miR-27a and miR-142-5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway. IUBMB Life. 2020;72:361-72.
  40. Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology. 2014;59:98-108.
  41. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus repli- cation in human hepatoma cells. J Virol. 2013;87:5270-86.
  42. Can U, Buyukinan M, Yerlikaya FH. The investigation of circulating microRNAs associated with lipid metabolism in childhood obesity. Pediatr Obes. 2016;11:228-34.
  43. Castaño C, Kalko S, Novials A, Párrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci USA. 2018;115:12158-63.
  44. Chen T, Zhang Y, Liu Y, Zhu D, Yu J, Li G, et al. MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling. Aging (Albany NY). 2019;11:7510-24.
  45. Srivastava A, Shankar K, Beg M, Rajan S, Gupta A, Varshney S, et al. Chronic hyperinsulinemia induced miR-27b is linked to adipocyte insulin resistance by targeting insulin receptor. J Mol Med (Berl). 2018;96:315-31.
  46. Chen YJ, Chueh LY, Lee SY, Ma PF, Chen PC, Hsu SH. Coordinated regulation of miR-27 by insulin/CREB/Hippo contributes to insulin resistance. Cell Signal. 2021;81:109930.
  47. Benito-Vicente A, Uribe KB, Rotllan N, Ramírez CM, Jebari-Benslaiman S, Goe- deke L, et al. miR-27b modulates insulin signaling in hepatocytes by regulating insulin receptor expression. Int J Mol Sci. 2020;21:8675.
  48. Yu Y, Du H, Wei S, Feng L, Li J, Yao F, et al. Adipocyte-derived exosomal MiR-27a induces insulin resistance in skeletal muscle through repression of PPARγ. Theranostics. 2018;8:2171-88.
  49. Xie W, Li L, Gong D, Zhang M, Lv YC, Guo DM, et al. Krüppel-like factor 14 inhibits atherosclerosis via mir-27a-mediated down-regulation of lipoprotein lipase expression in vivo. Atherosclerosis. 2019;289:143-61.
  50. Yu J, Lv Y, Di W, Liu J, Kong X, Sheng Y, et al. MiR-27b-3p regulation in browning of human visceral adipose related to central obesity. Obesity (Silver Spring). 2018;26:387-96.
  51. Wang S, Ai H, Liu L, Zhang X, Gao F, Zheng L, et al. Micro-RNA-27a/b negatively regulates hepatic gluconeogenesis by targeting FOXO1. Am J Physiol Endocrinol Metab. 2019;317:E911-E924.
  52. Zhang M, Wu JF, Chen WJ, Tang SL, Mo ZC, Tang YY, et al. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis. 2014;234:54-64.
  53. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dysli- pidemia. Hepatology. 2013;57:533-42.
  54. Ouimet M, Hennessy EJ, van Solingen C, Koelwyn GJ, Hussein MA, Ramkhelawon B, et al. miRNA targeting of oxysterol-binding protein-like 6 regulates choles- terol trafficking and efflux. Arterioscler Thromb Vasc Biol. 2016;36:942-51.
  55. Alvarez ML, Khosroheidari M, Eddy E, Done SC. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015;242:595-604.
  56. Khan AA, Agarwal H, Reddy SS, Arige V, Natarajan B, Gupta V, et al. MicroRNA 27a is a key modulator of cholesterol biosynthesis. Mol Cell Biol. 2020;40: e00470-19.
  57. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic stea- tohepatitis. Hepatology. 2003;37:544-50.
  58. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol. 2008;49:417-28.
  59. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43:298-304.
  60. Thulasingam S, Massilamany C, Gangaplara A, Dai H, Yarbaeva S, Subramaniam S, et al. miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells. Mol Cell Biochem. 2011;352:181-8.
  61. Zhao J, Du X, Wang M, Yang P, Zhang J. Salidroside mitigates hydrogen peroxide-induced injury by enhancement of microRNA-27a in human trabecular meshwork cells. Artif Cells Nanomed Biotechnol. 2019;47:1758-65.
  62. Zhao XR, Zhang Z, Gao M, Li L, Sun PY, Xu LN, et al. MicroRNA-27a-3p aggravates renal ischemia/reperfusion injury by promoting oxidative stress via targeting growth factor receptor-bound protein 2. Pharmacol Res. 2020;155:104718.
  63. Ebrahimpour S, Shahidi SB, Abbasi M, Tavakoli Z, Esmaeili A. Quercetin- conjugated superparamagnetic iron oxide nanoparticles (QCSPIONs) increases Nrf2 expression via miR-27a mediation to prevent memory dysfunction in dia- betic rats. Sci Rep. 2020;10:15957.
  64. Yang Q, Zhang D, Li Y, Li Y, Li Y. Paclitaxel alleviated liver injury of septic mice by alleviating inflammatory response via microRNA-27a/TAB3/NF-κB signaling pathway. Biomed Pharmacother. 2018;97:1424-33.
  65. Yao F, Yu Y, Feng L, Li J, Zhang M, Lan X, et al. Adipogenic miR-27a in adipose tissue upregulates macrophage activation via inhibiting PPARγ of insulin resis- tance induced by high-fat diet-associated obesity. Exp Cell Res. 2017;355:105-12.
  66. Xie N, Cui H, Banerjee S, Tan Z, Salomao R, Fu M, et al. miR-27a regulates inflammatory response of macrophages by targeting IL-10. J Immunol. 2014;193:327-34.
  67. Cheng Y, Du L, Jiao H, Zhu H, Xu K, Guo S, et al. Mmu-miR-27a-5p-dependent upregulation of MCPIP1 inhibits the inflammatory response in LPS-induced RAW264.7 macrophage cells. Biomed Res Int. 2015;2015:607692.
  68. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res. 2012;111:1198-207.
  69. Léveillé M, Estall JL. Mitochondrial dysfunction in the transition from NASH to HCC. Metabolites. 2019;9:233.
  70. Wu L, Wang Q, Guo F, Ma X, Wang J, Zhao Y, et al. Involvement of miR-27a-3p in diabetic nephropathy via affecting renal fibrosis, mitochondrial dysfunction, and endoplasmic reticulum stress. J Cell Physiol. 2021;236:1454-68.
  71. Li H, Liu J, Wang Y, Fu Z, Hüttemann M, Monks TJ, et al. MiR-27b augments bone marrow progenitor cell survival via suppressing the mitochondrial apoptotic pathway in type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313: E391-E401.
  72. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
  73. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233:109-22.
  74. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastro- enterol. 2014;20:7312-24.
  75. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 2009;583:759-66.
  76. Ji Y, Zhang J, Wang W, Ji J. Functional study of miR-27a in human hepatic stellate cells by proteomic analysis: comprehensive view and a role in myogenic tans-differentiation. PLoS One. 2014;9:e108351.
  77. Li Z, Ji L, Su S, Zhu X, Cheng F, Jia X, et al. Leptin up-regulates microRNA-27a/b- 3p level in hepatic stellate cells. Exp Cell Res. 2018;366:63-70.
  78. Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, et al. TGF-β signalling and liver disease. FEBS J. 2016;283:2219-32.
  79. Davoodian P, Ravanshad M, Hosseini SY, Khanizadeh S, Almasian M, Nejati Zadeh A, et al. Effect of TGF-β/smad signaling pathway blocking on expression profiles of miR-335, miR-150, miR-194, miR-27a, and miR-199a of hepatic stellate cells (HSCs). Gastroenterol Hepatol Bed Bench. 2017;10:112-7.
  80. Wang S, Li M, Zhao X, Wang H, Zhu J, Wang C, et al. Upregulation of KSRP by miR-27b attenuates schistosomiasis-induced hepatic fibrosis by targeting TGF- β1. FASEB J. 2020;34:4120-33.
  81. Zhang H, Yan XL, Guo XX, Shi MJ, Lu YY, Zhou QM, et al. MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. Oncotarget. 2018;9:1075-90.
  82. Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med. 2016;5:30.
  83. Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH -current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461-78.
  84. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma amino- transferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61:153-60.
  85. Valihrach L, Androvic P, Kubista M. Circulating miRNA analysis for cancer diagnostics and therapy. Mol Asp Med. 2020;72:100825.
  86. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, et al. Current state of circulating microRNAs as cancer biomarkers. Clin Chem. 2015;61:1138-55.
  87. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6:e23937.
  88. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99-103.
  89. Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C, et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016;22:9844-52.
  90. Ando Y, Yamazaki M, Yamada H, Munetsuna E, Fujii R, Mizuno G, et al. Asso- ciation of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Sci Rep. 2019;9:18856.
  91. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One. 2014;9:e105192.
  92. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853-8. 100. Yan L, Ma J, Zhu Y, Zan J, Wang Z, Ling L, et al. miR-24-3p promotes cell migration and proliferation in lung cancer by targeting SOX7. J Cell Biochem. 2018;119:3989-98. 101. Lynch SM, McKenna MM, Walsh CP, McKenna DJ. miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate. 2016;76:637-48. 102. Ehrlich L, Hall C, Venter J, Dostal D, Bernuzzi F, Invernizzi P, et al. miR-24 inhi- bition increases menin expression and decreases cholangiocarcinoma pro- liferation. Am J Pathol. 2017;187:570-80. 103. Wang N, Tan HY, Feng YG, Zhang C, Chen F, Feng Y. microRNA-23a in human cancer: its roles, mechanisms and therapeutic relevance. Cancers (Basel). 2018;11:7. 104. Yang X, Wu G, Yang F, He L, Xie X, Li L, et al. Elevated LINC00909 promotes tumor progression of ovarian cancer via regulating the miR-23b-3p/MRC2 axis. Oxid Med Cell Longev. 2021;2021:5574130. 105. Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer CJ, et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014;60:554-64. 106. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a mem- brane protein that facilitates retention of SREBPs in ER. Cell. 2002;110:489-500. 107. Engelking LJ, Liang G, Hammer RE, Takaishi K, Kuriyama H, Evers BM, et al. Schoenheimer effect explained-feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest. 2005;115:2489-98. 108. Kang M, Yan LM, Li YM, Zhang WY, Wang H, Tang AZ, et al. Inhibitory effect of microRNA-24 on fatty acid-binding protein expression on 3T3-L1 adipocyte differentiation. Genet Mol Res. 2013;12:5267-77. 109. Jin M, Wu Y, Wang J, Chen J, Huang Y, Rao J, et al. MicroRNA-24 promotes 3T3- L1 adipocyte differentiation by directly targeting the MAPK7 signaling. Biochem Biophys Res Commun. 2016;474:76-82. 110. Yu X, Lin Q, Wu Z, Zhang Y, Wang T, Zhao S, et al. ZHX2 inhibits SREBP1c- mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p. J Pathol. 2020;252:358-70. 111. Wang M, Li L, Liu R, Song Y, Zhang X, Niu W, et al. Obesity-induced over- expression of miRNA-24 regulates cholesterol uptake and lipid metabolism by targeting SR-B1. Gene. 2018;668:196-203. 112. Hall C, Ehrlich L, Meng F, Invernizzi P, Bernuzzi F, Lairmore TC, et al. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2(-/-) mice. J Surg Res. 2017;217:160-9. 113. Guan L, Hu X, Liu L, Xing Y, Zhou Z, Liang X, et al. bta-miR-23a involves in adipogenesis of progenitor cells derived from fetal bovine skeletal muscle. Sci Rep. 2017;7:43716. 114. Huang Y, Huang J, Qi R, Wang Q, Wu Y, Wang J. Effects of microRNA-23a on differentiation and gene expression profiles in 3T3-L1 adipocytes. Genes (Basel). 2016;7:92. 115.
  93. Borji M, Nourbakhsh M, Shafiee SM, Owji AA, Abdolvahabi Z, Hesari Z, et al. Down-regulation of SIRT1 expression by mir-23b contributes to lipid accumu- lation in HepG2 cells. Biochem Genet. 2019;57:507-21. 116. Dong Z, Li S, Wang X, Si L, Ma R, Bao L, et al. lncRNA GAS5 restrains CCl (4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway. Am J Physiol Gastrointest Liver Physiol. 2019;316: G539-G550. 117.
  94. Bang C, Fiedler J, Thum T. Cardiovascular importance of the microRNA-23/27/24 family. Microcirculation. 2012;19:208-14. 138. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human dis- eases. Mol Cancer. 2010;9:232. 139. Musto A, Navarra A, Vocca A, Gargiulo A, Minopoli G, Romano S, et al. miR-23a, miR-24 and miR-27a protect differentiating ESCs from BMP4-induced apoptosis. Cell Death Differ. 2015;22:1047-57. 140. Su D, Wang X, Ma Y, Hao J, Jinshen W, Yongqu L, et al. Nrf2-induced miR-23a- 27a-24-2 cluster modulates damage repair of intestinal mucosa by targeting the Bach1/HO-1 axis in inflammatory bowel diseases. Free Radic Biol Med. 2021;163:1-9. 141. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA- 23~27~24 clusters. Proc Natl Acad Sci USA. 2011;108:8287-92. 142. Wang Y, Zhang Y, Su X, Wang H, Yang W, Zan L Cooperative and independent functions of the miR-23a~27a~24-2 cluster in bovine adipocyte adipogenesis. Int J Mol Sci. 2018;19:3957. 143. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172:962-74. 144. Singh S, Narang AS, Mahato RI. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharmacol Res. 2011;28:2996-3015. 145. Xue J, Yang J, Luo M, Cho WC, Liu X. MicroRNA-targeted therapeutics for lung cancer treatment. Expert Opin Drug Discov. 2017;12:141-57. 146. Lai X, Eberhardt M, Schmitz U, Vera J. Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic Acids Res. 2019;47:7753-66. 147. Kadekar S, Nawale GN, Karlsson K, Ålander C, Oommen OP, Varghese OP. Syn- thetic design of asymmetric miRNA with an engineered 3' overhang to improve strand selection. Mol Ther Nucleic Acids. 2019;16:597-604. 148. Ramezani-Aliakbari F, Badavi M, Dianat M, Mard SA, Ahangarpour A. Trimeta- zidine increases plasma microRNA-24 and microRNA-126 levels and improves dyslipidemia, inflammation and hypotension in diabetic rats. Iran J Pharm Res. 2020;19:248-57. 149. Zheng T, Chen H. Resveratrol ameliorates the glucose uptake and lipid meta- bolism in gestational diabetes mellitus mice and insulin-resistant adipocytes via miR-23a-3p/NOV axis. Mol Immunol. 2021;137:163-73. 150. Liu H, Wang X, Wang ZY, Li L. Circ_0080425 inhibits cell proliferation and fibrosis in diabetic nephropathy via sponging miR-24-3p and targeting fibroblast growth factor 11. J Cell Physiol. 2020;235:4520-9. 151. Fan H, Zhang W. Overexpression of Linc 4930556M19Rik suppresses high glucose-triggered podocyte apoptosis, fibrosis and inflammation via the miR- 27a-3p/Metalloproteinase 3 (TIMP3) axis in diabetic nephropathy. Med Sci Monit. 2020;26:e925361. 152.
  95. Bai X, Geng J, Li X, Wan J, Liu J, Zhou Z, et al. Long noncoding RNA LINC01619 regulates microRNA-27a/forkhead box protein O1 and endoplasmic reticulum stress-mediated podocyte injury in diabetic nephropathy. Antioxid Redox Sig- nal. 2018;29:355-76. 153.
  96. Song J, Zhang H, Sun Y, Guo R, Zhong D, Xu R, et al. Omentin-1 protects renal function of mice with type 2 diabetic nephropathy via regulating miR-27a-Nrf2/ Keap1 axis. Biomed Pharmacother. 2018;107:440-6. 154. Lv L, Zhang J, Tian F, Li X, Li D, Yu X. Arbutin protects HK-2 cells against high glucose-induced apoptosis and autophagy by up-regulating microRNA-27a. Artif Cells Nanomed Biotechnol. 2019;47:2940-7. 155. Cai HA, Huang L, Zheng LJ, Fu K, Wang J, Hu FD, et al. Ginsenoside (Rg-1) promoted the wound closure of diabetic foot ulcer through iNOS elevation via miR-23a/IRF-1 axis. Life Sci. 2019;233:116525. 156. He L, Zhao X, He L. LINC01140 alleviates the oxidized low-density lipoprotein- induced inflammatory response in macrophages via suppressing miR-23b. Inflammation. 2020;43:66-73. 157. Zeng J, Deng Z, Zou Y, Liu C, Fu H, Gu Y, et al. Theaflavin alleviates oxidative injury and atherosclerosis progress via activating microRNA-24-mediated Nrf2/ HO-1 signal. Phytother Res. 2021;35:3418-27.

Cited by

Sorted by citations

Authors
Ru, L., Wang, X.-M., & Niu, J.-Q.
Affiliations
First Hospital of Jilin University (CN)
Venue
Acta Pharmacologica Sinica
Publisher
Springer Science and Business Media LLC
Published
2021-12-10
Volume
43
Issue
5
Pages
1167-1179
ISSN
  • 0253-9756 (ISSN-L)
  • 1671-4083
  • 1745-7254
DOI
10.1038/s41401-021-00819-w
PMC
PMC9061717
OpenAlex
W4200343858
Cited by
21
References
8
Citations by year
2026: 5 · 2025: 2 · 2024: 9 · 2023: 2 · 2022: 3
FWCI
0.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Pharmacologica Sinica (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Natural Science Foundation of Jilin Province (20210101446JC)
  • National Natural Science Foundation of China (81970519, 2017TD-08)
  • People's Government of Jilin Province
  • Fundamental Research Funds for the Central Universities (2017TD-08)
  • Program for Jilin University Science and Technology Innovative Research Team (2017TD-08)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
microRNA, non-alcoholic fatty liver disease, miR-27, miR-24, miR-23, lipid accumulation, oxidative stress, mitochondrial damage, inflammation, NAFLD diagnosis, NAFLD therapy
MeSH terms
Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, MicroRNAs, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review